IceCure Medical Q2 Revenue Up ~45%, U.S. Footprint Expands ~70%

ICCM Icecure Medical Ltd

$1.54 -1.91%

View chart & analysis →

NVDA +2.12% GLBE +1.14% RSKD -0.64% FNV +0.62% DLO +5.64% 8 more

1. 1IceCure Medical (ICCM) Q2 revenue grew approximately 45% on increased system sales and higher usage of disposable probes.
2. 2Its U.S. commercial footprint expanded around 70% following FDA early low-risk breast cancer authorization, with gross margin improving to 30%.
3. 3The company holds about $12 million in cash and raised roughly $8.5 million during the quarter, projecting first patient enrollment in the CHOICE trial within 3–4 weeks.

Source Moby +2 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →